NEW HOPE, Pa.–(BUSINESS WIRE)–VerdePharmHealth today announced the signing of an exclusive national agreement with HAI Health for the HealthyDose product line formulated by a highly respected oncologist, Dr. Alberto Bessudo.
“There is growing evidence that medical cannabis may be effective in helping patients manage certain types of cancers at various stages, in conjunction with and as an alternative to traditional medical treatments. Medical cannabis may also be effective in managing the side effects of cancer therapies and the symptoms of the disease. Unfortunately, most people wait too long after diagnosis to begin cannabis therapies. They begin looking for alternative therapy when conventional treatments haven’t worked, and the disease is already advanced, sometimes with a terminal diagnosis,” said Dr. Alberto Bessudo, founder & chief executive officer at HAI Health. “After careful consideration and diligence, we selected VerdePharmHealth given our alignment of mission and values for patient care, their solid commitment towards innovation in integrative medicine, and robust offering to healthcare providers and their patients.”
“Dr. Alberto Bessudo has been on the cutting edge of medicinal cannabis in patient care, developing integrative plans with cannabinoids targeted towards specific symptoms, without the numerous side effects of conventional pharmaceuticals and procedures. Dr. Bessudo and his team have designed synergistic formulations, which are comprised of curated ingredients that are specifically designed to work and support the body’s own functions and accelerate health,” said Dr, Ralph Boccia, oncologist, board member, & medical director at VerdePharmHealth. “As part of their ongoing commitment to quality medical cannabis products, the ingredients are grown without pesticides or herbicides, and several in the product line are organic. Furthermore, several tests are conducted, including testing for heavy metals, pesticides, mold and yeast, microbes, and cannabinoid potency, instilling a higher level of confidence for our provider member network and their patients.”
Both companies will further partner around systematic, structured real-world observational studies to better understand and improve the appropriate use of cannabinoids, support cost of care, improve quality of life, and treatment optimization paradigms, with HealthyDose Clinical Premium product made available through HAI Health and the clinical research platform and services, decision-support tools, patient engagement app, and data analytics provided by VerdePharmHealth.
VerdePharmHealth, the first organization of its kind in the U.S., provides comprehensive multi-specialty group purchasing, clinical solutions, and healthcare technology designed to drive high-level commitment and affordability for members through accessibility of quality cannabis products from prequalified manufacturers and leveraging of clinical services and robust technology to improve decisions for interventions at the point of care and capture real-world evidence. Utilizing retrospective data and clinical studies for decision-support and standardization of appropriate-use in the care delivery process is a central pillar towards achieving outcomes. For more information, visit www.verdepharmhealth.com or follow VerdePharmHealth on LinkedIn.
Contact: email@example.com or George Raupp, Chief Operating Officer 610.937.1175
About HAI Health
Our mission is wellness. Our team of biologists, nutritionists, pharma industry experts and medical scientists are committed to deliver clinical grade, GMP-certified products that balance and supplement the endocannabinoid system to make the life of patients with chronic illness, including cancer, better and longer.
Contact: HAI Health, Inc., 1650 N Coast Hwy 101, Suite B, Encinitas CA 92024.
Matters discussed in this release that are not statements of historical or current facts, such as expected savings and other expected benefits to members and suppliers, as discussed herein, are “forward-looking statements” which may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of VerdePharmHealth and its subsidiaries to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to VerdePharm’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside VerdePharm’s control. Forward-looking statements speak only as of the date they are made. VerdePharm undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.